Overall, our study elucidates that CB2R activation can promote TAMs-mediated phagocytosis of tumor cells by increasing CD36 expression, suggesting JWH133 could serve as a viable therapeutic approach to enhance the efficacy of chemotherapy in treating GBM. Here, CD36 is linked to glioblastoma.